Union européenne - croate - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - poremećaj erekcije - urologicals - liječenje erektilne disfunkcije kod odraslih muškaraca. da bi tadalafil bio učinkovit, potrebna je seksualna stimulacija. tadalafil lilly ne navodi za žene. liječenje znakova i simptoma benigne hiperplazije prostate kod odraslih muškaraca.

Union européenne - croate - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotska sredstva - xarelto, uvedene zajedno sa ацетилсалициловой kiselinom (ask) sami ili sa asc plus клопидогрел ili Тиклопидин, prikazana za prevenciju атеротромботических događaja kod odraslih pacijenata nakon akutnog koronarni sindrom (acs) s povišenom razinom кардиальных biomarkera. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Union européenne - croate - EMA (European Medicines Agency)

merck sharp dohme limited - vorapaxar sulfat - infarkt miokarda - antitrombotska sredstva - zontivityis što je prikazano za smanjenje атеротромботических događaja u odraslih bolesnika s poviješću infarkta miokarda (im)su uvedeni u suradnji s ацетилсалициловой kiselina (asa) i, ako je potrebno, klopidogrel; ili - simptom bolesti perifernih arterija(зпа), koji je uveden u suradnji s ацетилсалициловой kiselinom (ask) ili, ako je potrebno, klopidogrel.

Union européenne - croate - EMA (European Medicines Agency)

krka, d.d., novo mesto - clopidogrel (as hydrogen sulfate) - peripheral vascular diseases; stroke; acute coronary syndrome; myocardial infarction - antitrombotska sredstva - prevencija sekundarne prevencije атеротромботических događaja klopidogrel prikazan:odrasli pacijenti koji pate инфарктом miokarda (od nekoliko dana do manje od 35 dana), ishemijski moždani udar (od 7 dana prije manje od 6 mjeseci) ili instaliranim bolest perifernih arterija. za odrasle pacijente koji pate od akutne коронарным sindroma:- bez elevacije segmenta st akutna koronarna sindrom (nestabilna angina, ili ne-q-инфарктом miokarda), uključujući i bolesnike koji su patili ugradnje stenta nakon чрескожного koronarne intervencije, u kombinaciji s ацетилсалициловой kiselinom (ask). - porast segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. sprječavanje атеротромботических i тромбоэмболических događaja kada фибрилляции vrlo značajan:- kod odraslih bolesnika s фибрилляцией vrlo značajan, koje imaju najmanje jedan faktor rizika za razvoj srčanih događaja, nisu pogodni za liječenje антагонистами vitamina k (ВКА) i koji imaju nizak rizik od krvarenja, клопидогрел prikazan u kombinaciji s ask za prevenciju атеротромботических i тромбоэмболических događaja, uključujući i moždani udar.

Union européenne - croate - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotska sredstva - prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 za hemodinamski nestabilne ТЭЛА pacijenata). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Union européenne - croate - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Union européenne - croate - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - drugi gastrointestinalni trakt i metabolizam, lijekovi, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Monténégro - croate - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

dio stranog druŠtva "sanofi - aventis" - podgorica - nepoznat - sirup - 150mg/ml

Bosnie-Herzégovine - croate - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

viennapharm d.o.o. - Сухи ekstrakt timijana, tečni ekstrakt korijena bijelog sljeza - sirup - 0.12 g/15 ml+ 0,83 g/15 ml - 15 ml (1 kašika) sirupa sadrži: 0,12 g suhi ekstrakt timijana i 0,83 g tečni ekstrakt korijena bijelog sljeza

Union européenne - croate - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresivi - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.